What this is
- This analysis evaluates the effects of DPP-4 inhibitors, GLP-1 receptor agonists (GLP-1RA), and SGLT-2 inhibitors on cardiorenal outcomes.
- It includes data from 23 cardiovascular outcome trials (CVOTs) involving 181,143 participants.
- The findings assess the relative efficacy of these drug classes in reducing major adverse cardiovascular events () and other outcomes.
Essence
- SGLT-2 inhibitors and GLP-1RA outperform DPP-4 inhibitors in improving cardiorenal outcomes. SGLT-2 inhibitors are particularly effective in reducing hospitalization for heart failure and renal events.
Key takeaways
- SGLT-2 inhibitors significantly lower cardiovascular death (RR = 0.88) and total death (RR = 0.87) compared to DPP-4 inhibitors. GLP-1RA also reduce total death (RR = 0.87) but not cardiovascular death compared to DPP-4 inhibitors.
- SGLT-2 inhibitors reduce the risk of hospitalization for heart failure () by 31% compared to placebo and outperform GLP-1RA in this regard (RR = 0.76).
- Only GLP-1RA significantly reduce the risk of nonfatal stroke (RR = 0.84) compared to placebo, highlighting a unique benefit of this drug class.
Caveats
- No head-to-head trials directly compare these drug classes, relying instead on indirect evidence. This limits the strength of conclusions drawn from the analysis.
- Variability in trial designs, patient characteristics, and outcome definitions may affect the comparability of results across studies.
Definitions
- MACE: Major adverse cardiovascular events, including cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke.
- HHF: Hospitalization for heart failure, a critical outcome in assessing heart failure management.
AI simplified
Introduction
Diabetes has reached alarming levels. More than half a billion people are living with diabetes worldwide and it is estimated that by 2045 there will be 693 million people diagnosed with the condition [1]. In addition, 541 million people are estimated to have impaired glucose tolerance, which brings to more than one billion the number of people living with subtle or frank alteration of glucose metabolism. The most common cardiovascular (CV) manifestations in patients with type 2 diabetes are heart failure (HF), stable angina, nonfatal myocardial infarction (MI), peripheral arterial disease and ischemic stroke [2–4] which accounts for 60% of their deaths [5]. Chronic kidney disease (CKD) also contributes to the major disease burden of patients with type 2 diabetes [6]. Therefore, the esteem for diabetes-related causes of death in 2021 have been updated to 6.7 million [1].
The quite unexpected positive cardiorenal outcomes that have emerged from the cardiovascular outcomes trials (CVOTs) with both glucagon like peptide-1 receptors agonists (GLP-1RA) and sodium-glucose co-transporter 2 (SGLT-2) inhibitors have produced a shift of diabetes management from the meticulous glycemic control alone to the simultaneous improvement of CV outcomes. Therefore, almost all scientific guidelines now recommend specific treatments for patients with type 2 diabetes based on CVOTs data, namely adding to metformin a SGLT-2 inhibitor or a GLP-1RA with proven CV disease benefit in patients with type 2 diabetes and CV disease, established kidney disease, or HF [7–10]. Owing to their lack of efficacy on cardiorenal outcomes, dipeptidyl-peptidase (DPP-4) inhibitors are only recommended to control hyperglycemia. There are also other practical reasons to prescribe these drugs in people with type 2 diabetes, because all three classes are associated with relatively low risk of hypoglycemic events, while patients treated with GLP-1RA and SGLT-2 inhibitors may also benefit from weight loss [11].
The cardiorenal effects of both GLP-1RA and SGLT-2 inhibitors can be summarized as follows: GLP-1RA have moderate benefits on MACE (major cardiovascular events), may reduce all-cause mortality and hospitalization for HF (HHF), and have a robust effect in reducing the incidence of macroalbuminuria [12]; SGLT-2 inhibitors cause robust reduction of HHF and the renal outcome, and moderate reduction of CV or total deaths and MACE [13]. However, data directly comparing GLP-1RA and SGLT-2 inhibitors are lacking, which limit the choice of clinicians between them. An indirect help may come from network meta-analysis, which is a technique for comparing three or more interventions simultaneously in a single analysis by combining both direct and indirect evidence across a network of studies. Previous similar exercises [14, 15] have indicated that SGLT-2 inhibitors are superior to GLP-1RA in reducing HHF and the renal outcome. However, new data on this subject continue to be released which adds new evidence to the therapeutic scenario.
In this current network meta-analysis, we evaluated 23 CVOTs, including the most recently published trials AMPLITUDE-O and EMPEROR-P. We aimed to compare the relative efficacy of SGLT-2 inhibitors, GLP-1RA and DPP-4 inhibitors in terms of cardiorenal outcomes.
Methods
Search strategy and study selection
This meta-analysis was performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines [16]. The protocol has not been registered in any platform. We searched PubMed, EMBASE and the Cochrane Database of Systematic Reviews to identify English-language studies published up until 10 December 2021. The search was limited to outcome trials evaluating the efficacy of DPP-4 inhibitors, GLP-1RA and SGLT-2 inhibitors on cardiovascular, heart failure or renal outcomes in adult patients with or without type 2 diabetes. The terms used for the research were “DPP-4 inhibitors”, “GLP-1 receptor agonists”, “SGLT-2 inhibitors”, “MACE”, “heart failure”, “renal outcome”, “total death” “cardiovascular death” and their synonyms and related keywords. The search was filtered to include only randomized controlled trials (RCTs) or meta-analyses of human data. The prespecified selection criteria included: (1) RCTs reporting desired cardiovascular or renal outcomes; (2) RCTs completed before the FDA guidance of 2008 [17] and (3) follow-up duration of at least 6 months.
Data extraction and quality assessment
Data were extracted by D.G. and M.L., with conflicts over study inclusion resolved by consensus. Results in trial reports (primary trial results and subsequent secondary publications), and their accompanying Additional file 1, were used as the primary source of information. The retrieved data included study characteristics, characteristics of patients, interventions, and outcome measures, that included the hazard ratios (HR) and confidence intervals (CI) for cardiorenal outcomes. The Cochrane Collaboration Risk-of-Bias tool was used for quality assessment of the RCTs [18], including sequence generation, allocation concealment, blinding, incomplete outcome data, and selective outcome reporting. Risk of bias was graded as unclear, high, or low.
Outcomes
The primary outcome in our network meta-analysis was MACE, defined as the composite of cardiovascular mortality, nonfatal myocardial infarction (MI), and nonfatal stroke. Co-primary outcomes were cardiovascular and total death. Secondary outcomes included nonfatal MI, nonfatal stroke, HHF and renal composite outcome, defined in most trials as a composite of progression to end-stage renal disease or a sustained decrease of at least 40% in estimated glomerular filtration rate (eGFR). The definitions of outcomes were those used in each trial.
Data synthesis and analysis
The comparison of outcomes among the different glucose-lowering drug classes was made using a frequentist approach for direct and indirect treatment comparisons for each endpoint [19]. For all pair wise comparisons, Risk ratios (RRs) and 95% Confidence Interval (CI) were used as the meta-analytic measure of association between treatment and the incidence of events. The overall heterogeneity of all the comparisons was assessed using the I2 statistic, in which values of > 25%, > 50% and > 75% correspond to low, moderate, and high heterogeneity, respectively. There was no need to evaluate the inconsistency between the direct (any class of drugs vs another class) and indirect (any class of drugs vs placebo) effects in the network meta-analysis, as there was no trial that compared any two classes in all the trials. Publication bias was assessed with the Egger test [20]. The trim-and-fill method [21] was used to estimate the effect of publication bias, if any. The relative ranking of the different treatment was estimated for each outcome using p-score [22]. The network analysis was performed using R (version 4.1.2, updated by 21 November 2021) netmeta package. Other statistical analyses were conducted, and forest plots created using Stata software (version 16.0, Stata Corp., College Station, TX).
Results
Search and risk of bias
Of the 54 articles assessed for eligibility, 23 RCTs (References 1–23 in the Additional file 1) fulfilled the inclusion criteria and were included in the meta-analysis (Additional file 1: Fig. S1). Their characteristics are summarized in Table 1. The participants were all adults (> 18 years old) patients and all trials were multinational and sponsored by industry. The trials have been published between 2013 and 2021, with four trials published in 2021. All trials were of parallel group, double-blind design, and their mean duration ranged from 0.75 (SOLOIST-WHF) to 5.4 years (REWIND). The populations studied ranged in size from 1222 (SOLOIST-WHF) to 17,160 (DECLARE) and were of similar age (range 61 to 71.9 years). Of these trials, four compared DPP-4 inhibitors against placebo (SAVOR-TIMI 53, EXAMINE, TECOS, CARMELINA), eight compared GLP-1RA against placebo (ELIXA, LEADER, SUSTAIN-6, EXSCEL, HARMONY, REWIND, PIONEER 6, AMPLITUTE-O) and eleven compared SGLT-2 inhibitors against placebo (EMPA-REG, CANVAS, DECLARE, CREDENCE, DAPA-HF, DAPA CKD, VERTIS-CV, EMPEROR-R, SCORED, SOLOIST-WHF, EMPEROR-P). The participants in the studies were 43,522 with DPP-4 inhibitors, 60,080 with GLP-1RA, and 77,541 with SGLT-2 inhibitors, for a total number of 181,143 participants. At the present, there is still no published or in progress trial directly comparing the cardiorenal outcomes of these three classes of drugs. The primary outcomes for the 23 trials are also given in Table 1. According to the Cochrane Collaboration’s tool for assessing risk of bias, all trials met the criteria for low risk of bias (Additional file 1: Table S1, Fig. S2).
| Trial/year of publication | Study drug/mean follow up (years) | Participants (n) | Age mean/median age (years) | Male sex (n, %) | Participants with prior CV disease (%) | Primary outcome | Study funder |
|---|---|---|---|---|---|---|---|
| DPP-4 inhibitors | |||||||
| SAVOR-TIMI53/2013 | Saxagliptin/2.1 | 16,492 | 65 | 11,050 (67%) | 78 | MACE | AstraZeneca |
| EXAMINE/2013 | Alogliptin/1.5 | 5380 | 61 | 3658 (68%) | 100 | MACE | Takeda |
| TECOS/2015 | Sitagliptin/3.0 | 14,523 | 65 | 10,311 (71%) | 100 | MACE | Merck |
| CARMELINA/2019 | Linagliptin/2.2 | 6979 | 66 | 4788 (68.6%) | 57 | MACE | Boehringer/Lilly |
| GLP-1RA | |||||||
| ELIXA, 2015 | Lixisenatide/2.1 | 6068 | 60.3 | 3174 (69.3%) | 100 | MACE | Sanofi |
| LEADER/2016 | Liraglutide/3.8 | 9340 | 64.3 | 6003 (64.3%) | 81 | MACE | NovoNordisk |
| SUSTAIN-6/2016 | Semaglutide/2.1 | 3297 | 64.6 | 2002 (60.7%) | 83 | MACE | NovoNordisk |
| EXSCEL/2017 | Exenatide/3.2 | 14,752 | 62 | 9149 (62%) | 73.1 | MACE | Amylin |
| HARMONY/2018 | Albiglutide/1.6 | 9463 | 64.1 | 6569 (69.4%) | 100 | MACE | GlaxoSmithKline |
| REWIND/2019 | Dulaglutide/5.4 | 9901 | 66.2 | 5312 (53.7%) | 31.4 | MACE | Boehringer/Lilly |
| PIONEER 6 /2019 | Semaglutide/1.3 | 3183 | 66 | 2176 (68.4%) | 84.7 | MACE | NovoNordisk |
| AMPLITUDE-O/2021 | Epfeglenatide/1.8 | 4076 | 64.5 | 2732 (67%) | 89.6 | MACE | SANOFI |
| SGLT-2 inhibitors | |||||||
| EMPA-REG/2015 | Empagliflozin/3.1 | 7020 | 63.2 | 5016 (71.5%) | 99 | MACE | Boehringer/Lilly |
| CANVAS/2017 | Canagliflozin/2.4 | 10,142 | 63.2 | 6509 (64.2%) | 66 | MACE | Janssen |
| DECLARE/2019 | Dapagliflozin/4.2 | 17,16 | 63.8 | 10,738 (62.6%) | 40.6 | MACE | AstraZeneca |
| CREDENCE/2019 | Canagliflozin/2.6 | 4401 | 63 | 2907 (66.1%) | 50.4 | Composite renal | Janssen |
| DAPA-HF/2019 | Dapagliflozin/1.5 | 4744 | 66 | 3131 (66%) | 100 | HHF or CV death | AstraZeneca |
| VERTIS-CV/2020 | Ertugliflozin/3.5 | 8246 | 64.4 | 5769 (70%) | 100 | MACE | Merck |
| DAPA-CKD/2020 | Dapagliflozin/2.4 | 4304 | 61.8 | 2879 (66.9%) | 38 | Composite renal | AstraZeneca |
| EMPEROR-R/2020 | Empagliflozin/1.3 | 3730 | 66.8 | 2837 (76%) | 100 | HHF or CV death | Boehringer/Lilly |
| SCORED/2021 | Sotagliflozin/1.3 | 10,584 | 69 | 5896 (55.7%) | NA | HHF or CV death | Sanofi/Lexicon |
| SOLOIST-WHF/2021 | Sotagliflozin/0.75 | 1222 | 70 | 810 (63.3%) | 100 | HHF or CV death | Sanofi/Lexicon |
| EMPEROR-P/2021 | Empagliflozin/2.2 | 5988 | 71.9 | 3317 (55.4%) | 100 | HHF or CV death | Boehringer/Lilly |
Outcomes
Figure 1 shows the network of comparisons for the outcomes. Figure 2 and Additional file 1: Fig. S3 show the results for the outcome MACE: both GLP-1RA and SGLT-2 inhibitors were associated with a lower risk for MACE (13% and 11%, respectively) as compared with placebo, and a lower risk for MACE as compared with DPP-4 inhibitors (12% and 11%, respectively). Moreover, the comparison between DPP-4 inhibitors and placebo demonstrated no difference in their risk for MACE (RR = 0.99, 95% CI 0.93–1.06). The comparison between GLP-1RA and SGLT-2 inhibitors also show no difference in their risk for MACE (RR = 0.98, 95% CI 0.91–1.07). P-rank scores show that GLP-1RA were ranked first in reducing the risk of MACE (88.8%) while SGLT-2 inhibitors were ranked second (77.5%) (Table S2). The overall heterogeneity for MACE was low (I2 = 15.3%, 95% uncertainty intervals, 0 and 52.3%) (Table S3). There was some evidence of asymmetry for MACE (Egger test, P = 0.059), suggesting a potential threat of publication bias; however, the trim-and-fill method indicated that this publication bias did not change the statistical significance of the estimate.
As for the single components of MACE, Fig. 2 and Additional file 1: Fig. S4 show that both GLP-1RA and SGLT-2 inhibitors were associated with a lower risk for nonfatal MI as compared with placebo (9% and 13%, respectively), or with DPP-4 inhibitors (10% and 14%, respectively), which was significant for the comparison between SGLT-2 and DPP-4 inhibitors only. The comparison between GLP-1RA and SGLT-2 inhibitors shows no difference in their risk for nonfatal MI (RR = 1.04, 95% CI 0.92–1.19). P-rank scores show that SGLT-2 inhibitors were ranked first in reducing nonfatal MI (90.4%) (Additional file 1: Table S2). As for nonfatal stroke, Fig. 2 and Additional file 1: Fig. S5 show that GLP-1RA were associated with lower risks as compared with placebo (16% lower risk), DPP-4 inhibitors (15% lower risk) and SGLT-2 inhibitors (10% lower risk), but the difference was statistically significant as compared with placebo only. P-rank scores show that GLP-1RA were ranked first in reducing nonfatal MI (95.8%) (Additional file 1: Table S2). As for CV death, Fig. 3 and Additional file 1: Fig. S6 show that both GLP-1RA and SGLT-2 inhibitors were associated with a lower risk (13% and 14%, respectively) as compared with placebo and DPP-4 inhibitors (11% and 12%, respectively), although the difference in risks was significant for SGLT-2 vs DPP-4 inhibitors only. There was no difference in the risk of CV death when GLP-1RA were compared with SGLT-2 inhibitors. P-rank scores show that SGLT-2 inhibitors were ranked first in reducing CV death (84.8%) (Additional file 1: Table S2). The overall heterogeneity levels were 24.4% (95% uncertainty intervals, 0 and 54.9%) for nonfatal MI (moderate), 11.1% (95% uncertainty intervals, 0 and 48.0%) for nonfatal stroke (low) and 15.8% (95% uncertainty intervals, 0 and 49.9%) for CV death (moderate) (Additional file 1: Table S3). The Egger test for these outcomes indicated some asymmetry for CV death only (P = 0.10).
Figure 3 and Additional file 1: Fig. S7 show the results for total death. Both GLP-1RA and SGLT-2 inhibitors were associated with the same lower risk (12%) as compared with placebo, and the same lower risk as compared with DPP-4 inhibitors (13%). The comparison between GLP-1RA and SGLT-2 inhibitors shows no difference in their risk for total death (RR = 1.00, 95% CI 0.91–1.11). P-rank scores show that SGLT-2 inhibitors were ranked first in reducing total death (84.0%) and GLP-1RA were ranked second (81.9%) (Additional file 1: Table S2). The overall heterogeneity for total death was I2 = 33.7% (95% uncertainty intervals, 0 and 60.9%) (moderate) (Additional file 1: Table S3). There was some evidence of publication bias (Egger test, P = 0.94), but the trim-and-fill method indicated that this publication bias did not impact the estimate.
Figure 3 and Additional file 1: Fig. S8 show the results for HHF. Both GLP-1RA and SGLT-2 inhibitors were associated with a lower risk (10% and 31%, respectively) as compared with placebo, and an even greater lower risk as compared with DPP-4 inhibitors (15% and 35%, respectively). Moreover, SGLT-2 inhibitors were associated with a lower risk for HHF as compared with GLP-1RA (RR = 0.76, 95% CI 0.68–0.85). P-rank scores show that SGLT-2 inhibitors were ranked first in reducing HHF (100%) (Additional file 1: Table S2). The overall heterogeneity for HHF was I2 = 0% (95% uncertainty intervals, 0 and 48.0%) (null) (Additional file 1: Table S3), with no evidence of publication bias (Egger test, P = 0.413).
Figure 3 and Additional file 1: Fig. S9 show the results for the renal outcome which was different among trials (Table 2). SGLT-2 inhibitors were associated with lower risk of renal outcome as compared with placebo (36% lower risk), DPP-4 inhibitors (40% lower risk) and GLP-1RA (22% lower risk). Moreover, GLP-1RA were associated with lower risk for renal outcomes as compared with either placebo (18% lower risk) or DPP-4 inhibitors (22% lower risk). P-rank scores show that SGLT-2 inhibitors were ranked first in reducing renal outcome (100%) (Additional file 1: Table S2). The overall heterogeneity for renal outcome was I2 = 42.3% (95% uncertainty intervals, 0 and 68.0%) (moderate) (Additional file 1: Table S3) with no evidence of publication bias.
Figure 4 and Additional file 1: Table S5 show the overall effects of the three classes of drugs on cardiorenal endpoints by the network meta-analysis using the frequentist approach.
The network of comparisons for the outcomes. The numbers on the arrows indicate the number of comparisons with placebo for each outcome
Forest plot of the network meta-analysis of MACE, nonfatal myocardial infarction, and nonfatal stroke. DPP-4i: dipeptydil-peptidase-4 inhibitors; Pl: placebo; GLP-1RA: glucagon-like peptide-1 receptor agonists; SGLT-2i: sodium-glucose cotransporter-2 inhibitors
Forest plot of the network meta-analysis of cardiovascular death, total death, hospitalization for heart failure, and renal outcome. DPP-4i: dipeptydil-peptidase-4 inhibitors; Pl: placebo; GLP-1RA: glucagon-like peptide-1 receptor agonists; SGLT-2i: sodium-glucose cotransporter-2 inhibitors
Summary “at glance” of the network meta-analysis comparing the effects of SGLT-2 inhibitors, GLP-1RA and DPP-4 inhibitors on cardiorenal outcomes. The symbol = indicates non significantly different; the symbol > indicates significantly different
| SAVOR-TIMI 53 | Doubling of creatinine level, initiation of dialysis, renal transplantation, or creatinine > 6.0 mg/dl |
| EXAMINE | Renal dialysis |
| TECOS | Renal failure |
| CARMELINA | End stage renal disease, death due to kidney failure, or sustained decrease of ≥ 40% in eGFR from baseline |
| ELIXA* | Doubling of serum creatinine |
| LEADER | New onset, persistent macroalbuminuria, persistent doubling of serum creatinine along with an eGRF < 45 ml/min/1.73 m, need of renal-replacement therapy or death from kidney disease2 |
| SUSTAIN-6 | Persistent macroalbuminuria, persistent doubling of serum creatinine along with a creatinine clearance < 45 ml/min/1.73 m, need of continuous renal-replacement therapy2 |
| EXSCEL | New-onset macroalbuminuria, 40% reduction of eGFR, initiation of renal replacement therapy, and death from renal causes |
| HARMONY | Change in eGFR, worsening renal function (safety outcomes) |
| REWIND | New-onset macroalbuminuria (UACR > 33.9 mg/mmol), ≥ 30% decline in eGRF, or new renal replacement therapy comprising dialysis or renal transplantation |
| PIONEER 6 | Not reported |
| AMPLITUDE-O | A decrease in the eGFR of ≥ 40% for ≥ 30 days, end-stage kidney disease (defined as dialysis for ≥ 90 days, kidney transplantation, or an eGFR of < 15 ml per minute per 1.73 m2 for ≥ 30 days), or death from any cause |
| EMPA-REG | A doubling of the serum creatinine level, the initiation of renal-replacement therapy, or death from renal disease |
| CANVAS | ≥ 40% reduction in eGFR, renal-replacement therapy, or renal death |
| DECLARE | ≥ 40% decrease in eGFR to < 60 ml/min/1.73 m, ESRD, or death from renal cause2 |
| DAPA-HF | ≥ 50% sustained decline eGFR or end-stage renal disease or renal death |
| CREDENCE | End-stage kidney disease, doubling of serum creatinine level, or renal death |
| VERTIS-CV | Death from renal causes, renal replacement therapy, or doubling of the serum creatinine level |
| DAPA-CKD | Sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal causes |
| EMPEROR-R | Chronic dialysis or renal transplantation or a profound, sustained reduction in the estimated GFR |
| SCORED | First occurrence of a sustained decrease of ≥ 50% in the eGFR from baseline for ≥ 30 days, long-term dialysis, renal transplantation, or sustained eGFR of < 15 ml/min/1.73 mfor ≥ 30 days2 |
| SOLOIST-WHF | Not reported |
| EMPEROR-P | The rate of decline in the eGFR during double-blind treatment |
Discussion
The present network meta-analysis included the most recent published CVOTs, thus providing the most contemporary assessment of the total available evidence for DPP-4 inhibitors, GLP-1RA and SGLT-2 inhibitors and their cardiorenal outcomes. The results of our analysis confirm the lack of any benefit by DPP-4 inhibitors on cardiorenal outcomes in people with type 2 diabetes [22]. Although past meta-analyses reported substantial reductions in MACE with DPP-4 inhibitors [23], their conclusions were based on studies with small sample sizes and limited numbers of cardiovascular events, which have not been confirmed by the four CVOTs specifically designed to assess the CV safety of DPP-4 inhibitors. Our analysis also confirms that GLP-1RA, when compared with placebo, reduce the risk of MACE, total death, HHF, and the composite renal outcome [12]. Finally, when compared with placebo, SGLT-2 inhibitors are associated with a robust reduction of hospitalization for HHF and renal outcome, and a moderate reduction of CV and total death, and MACE [13].
As for the network meta-analysis, Fig. 4 shows an “at glance” summary of the results obtained. According to our data, SGLT-2 inhibitors show the highest probability to be superior to GLP-1RA and DPP-4 inhibitors in terms of HHF and the composite renal outcome, while GLP1-RA are superior to DPP-4 inhibitors for both outcomes. These results are based on 22 comparisons for HHF and 18 comparisons for the renal outcome. As for mortality, both SGLT-2 inhibitors and GLP-1RA are similar in reducing both total and CV deaths, but SGLT-2 inhibitors only are superior to DPP-4 inhibitors for both deaths, whereas GLP-1RA are superior to DPP-4 inhibitors for total death, but equal for CV death. These results are based on all 23 comparisons. As for nonfatal stroke, GLP-1 RA are the only drug class that significantly reduces nonfatal stroke, as compared with placebo, without any difference among the three classes of drugs. These results, as those for nonfatal MI and MACE, are based on 18 comparisons. As for nonfatal MI, both SGLT-2 inhibitors and GLP-1RA are similar, but SGLT-2 inhibitors only are superior to DPP-4 inhibitors. Finally, for the primary endpoint MACE, both SGLT-2 inhibitors and GLP-1RA are similar and both are superior to DPP-4 inhibitors. For the first time, clinicians have the option to save lives with antidiabetic drugs in certain groups of patients with type 2 diabetes.
The inclusion in our network analysis of the AMPLITUDE-O and EMPEROR-P data have modified the conclusions of the most recent similar analysis [15] indicating that SGLT-2 inhibitors increased the risk of stroke as compared with GLP-1RA and that GLP-1RA are superior to DPP-4 inhibitors as for nonfatal MI. Although EMPEROR-R enrolled patients with and without type 2 diabetes, the primary outcome of the trial (a composite of CV death and hospitalization for HF) was almost identical in both groups, suggesting that the different population didn’t affect the results, at least for the primary outcome.
Owing to intrinsic limitations of network meta-analysis, we avoided to analyze the effects of these drugs in several subgroups—e.g., as stratified by age or the presence of CV disease or type 2 diabetes—to avoid type 1 error due to the many subgroup analyses. Moreover, these analyses have already been done in conventional meta-analyses, showing for SGLT-2 inhibitors the lack of significant difference in the reduced risk of the composite outcome (CV death + HHF) in patients with or without type 2 diabetes or in subjects of 65 years of age or younger vs those older than 65 years of age [13]. Moreover, GLP-1RA reduced the risk of MACE by 14% in the overall diabetic population, with an apparent greater effect in patients with established CV disease (16% vs 6% reduction, respectively), although the lack of significant interaction between subgroups does not allow to separate them [12].
As evidence of the efficacy of SGLT-2 inhibitors continued to grow, trials on these drugs have expanded their study populations from diabetes patients only to also include patients with HF or CKD in the absence of diabetes. On the basis of results of the most recent CVOTs (DAPA-HF, DAPA-CKD, EMPEROR-R), the FDA has approved dapagliflozin (2020) and empagliflozin (2021) to reduce risk for CV death and HF hospitalization in adults with HF and reduced ejection fraction regardless of whether they have diabetes [24, 25]. FDA has also approved dapagliflozin for treatment for CKD (2021) [26] and has given priority review for empagliflozin to potentially treat heart failure not associated with left ventricular ejection fraction [27]. SGLT-2 inhibitors and GLP-1RA should, therefore, be considered evidence-based treatments for patients with type 2 diabetes after metformin. In theory, SGLT-2 inhibitors should be considered before GLP-1RA because of the reduction in both CV and total deaths associated with their use. In practice, it seems better to tailor the choice to different patients, depending on the preference of the route of administration (oral vs injectable), the presence of intolerance or side-effects, and contraindications; in these cases, one can be switched to another, or they can both be given, if the glycemic target is not attained.
To confirm that CVOTs findings are consistent in more diverse populations reflective of patients in the clinical practice, we may need to look beyond clinical trials to real-world evidence studies. In a meta-analysis evaluating the real-world effect of SGLT-2 inhibitors on cardiovascular outcome in patients with type 2 diabetes, Li et al. [28] included fourteen trials enrolling 3,157,259 patients. They found that the predominant impact of SGLT-2 inhibitors is on cardiovascular outcome was driven predominantly by reduction in MACE, total death, HHF, MI, stroke, and CV death. These results were even greater than those recorded in CVOTs. Quite similar results, although of lesser extent and for lesser outcomes, have been observed with GLP-1RA [29].
Our network meta-analysis has certain limitations. Firstly, there was no head-to-head CVOT directly comparing these antidiabetic drug classes; therefore, the comparative effects were generated with indirect evidence, and caution must be exercised when interpreting data from indirect comparison of CVOTs. Moreover, different drugs were used within each drug class, and there could be within-class differences. However, there are on the horizon no cardiorenal outcome studies comparing SGLT-2 inhibitors with GLP-1RA, so it is likely that we must rely on indirect comparisons. Secondly, as for most meta-analyses, we did not have patient-level data, limiting the scope for adjustments. Finally, there were differences in trial designs, patient characteristics, background therapy, and endpoint definitions. However, and despite these limitations, SGLT-2 inhibitors or a GLP-1RA with proven CV disease benefit are recommended in patients with type 2 diabetes and CV disease, established kidney disease, or HF [7–10].
Strengths of the present meta-analysis are the inclusion of all CVOTs published by 10 December 2021, the very large number of participants, the high quality of the trials which minimizes the risk of bias, and the absence of significant heterogeneity in most analyses, which ranged from absent to low or moderate. The clinical relevance of these results seems also highlighted by the evidence that for some outcomes the clinical benefit is consistent irrespective of the presence of type 2 diabetes [13], advanced age [13, 30], and the background cardiorenal disease [12, 15, 31]. Accordingly, people with type 2 diabetes, cardiovascular disease, heart failure, or chronic kidney disease should be treated appropriately with an SGLT-2 inhibitor or GLP-1RA, even because more adults with type 2 diabetes in the US have suboptimal glycemic control now compared to 10 years ago, associated with a resurgence in vascular diabetic complications [32].
Conclusions
In summary, SGLT-2 inhibitors are superior in reducing cardiovascular death, hospitalization for HF, and renal events among the new antidiabetic drug classes. Both SGLT-2 inhibitors and GLP-1 RA can reduce MACE. In terms of cardiovascular and renal outcome, DPP-4 inhibitors are comparable to placebo and are inferior to the other two drug classes. SGLT-2 inhibitors and GLP-1RA, should be the preferred treatment for patients with type 2 diabetes and cardiorenal diseases after metformin. It is not by chance that the most recent clinical guidelines [10] continue to advocate the use of antidiabetic drugs that have been proven to reduce cardiovascular events and mortality.
Supplementary Information
Acknowledgements
Not applicable.
Abbreviations
Authors' contributions
DG and KE contributed to the study conception and literature search, screened the articles, contributed to data extraction and data analysis, and wrote the manuscript. ML, MIM and BS contributed to the literature search, data extraction, and manuscript drafting. SS, DG, and PC performed the statistical analysis. All authors acknowledge full responsibility for the analyses and interpretation of the report and have read and approved the final manuscript. DG is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors read and approved the final manuscript.
Funding
None.
Availability of data and materials
All data generated or analyzed during this study are included in this published article and in its Additional file.
Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
DG received honoraria for speaking at meetings from Novartis, Sanofi, Eli Lilly and Company, AstraZeneca, and Novo Nordisk. MIM received honoraria for speaking at meetings from AstraZeneca, Novo Nordisk, Bruno Farmaceutici, Mundipharma, and Sanofi. KE received honoraria for speaking at meetings from Novartis, Sanofi Aventis, Eli Lilly and Company, AstraZeneca, Boehringer Ingelheim, and Novo Nordisk. No other potential conflicts of interest relevant to this article were reported.
Footnotes
References
Associated Data
Supplementary Materials
Data Availability Statement
All data generated or analyzed during this study are included in this published article and in its Additional file.